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Background
HIV Vaccine trials bring the significant risk of vaccine-
induced HIV seropositivity(VISP) resulting in negative
personal consequences for vaccinees. The overall rate of
VISP in licensed EIA tests is reported as 41.7%(JAMA
2010;304:275-283). We have developed and modified the
peptide-based HIV Selectest immunoassay(J.Virol
2006;80:2092-2099), which discriminates VISP from true
HIV infection, in a format suitable for routine laboratory
use, and have evaluated its performance on samples
from three Phase III HIV vaccine trials.
Methods
The HIV Selectest incorporated five synthetic peptides in a
single well microplate ELISA. Serum panels evaluated
comprised well-characterized HIV-positive sera from
clades A,B and C, worldwide panels comprising all major
clades, blood donor controls, and sera from vaccine and
placebo recipients in RV144, Vax003 and Vax004 trials.
Results
360 serum samples from the RV144 vaccine trial,
including 170 samples from vaccinated subjects at the
peak immune response, 120 pre-immune samples, and
70 subjects from the placebo group were tested on the
HIV Selectest. One (1) subject(0.6%) among the vaccine
recipient group yielded false-positive results, while 3 pla-
cebo recipients (4.3%) and 1 pre-immune serum sample
(0.8%) were also false positive in the HIV Selectest. All
false-positive samples demonstrated broad non-specific
cross-reactivity that was not restricted to a particular
HIV-specific peptide.
Similar results were obtained with samples from the
VAX003 and VAX004 vaccine trials. One subject out of
87(1.2%) tested after the final vaccination(7thvisit) at the
peak of the immune response was detected as false posi-
tive. Two additional samples out of 96(2.1%) taken after
the 4thvisit were likewise detected as false-positive, bring-
ing the average false-positive rate for both groups to 1.6%.
Blood donors yielded a statistically equivalent false-posi-
tive rate of 1.2%. Detection sensitivity for HIV positive
samples was 96% among 648 serum samples representing
different clades.
Conclusion
The HIV Selectest ELISA has demonstrated significantly
better discrimination of VISP than currently licensed
HIV serologic assays.
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